Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18372406 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Thomas RS, et al. (2008) Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J Mol Endocrinol 40, 173-84 18372406
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S104-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S104‑p, ER‑alpha (mouse): S108‑p, ER‑alpha (rat): S109‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
KINASE ERK2 (human)
KINASE CDK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) activation of upstream enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
KINASE ERK1 (human) activation of upstream enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester, estrogen increase
HRas (human) increase activated
RAF1 (human) increase activated
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
estrogen increase
U0126 estrogen no effect upon treatment-induced increase
4-HT increase
U0126 4-HT inhibit treatment-induced increase
ICI 182,780 increase
U0126 ICI 182,780 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  transcription, altered

S106-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S106‑p, ER‑alpha (mouse): S110‑p, ER‑alpha (rat): S111‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) activation of upstream enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
KINASE ERK2 (human) activation of upstream enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester, estrogen increase
HRas (human) increase activated
RAF1 (human) increase activated
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
estrogen increase
U0126 estrogen no effect upon treatment-induced increase
4-HT increase
U0126 4-HT no effect upon treatment-induced increase
ICI 182,780 increase
U0126 ICI 182,780 no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (process):  transcription, altered

S118-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S118‑p, ER‑alpha (mouse): S122‑p, ER‑alpha (rat): S123‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), COS (fibroblast), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK2 (human)
KINASE ERK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) activation of upstream enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
KINASE ERK2 (human) activation of upstream enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester, estrogen increase
HRas (human) increase activated
RAF1 (human) increase activated
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
estrogen increase
U0126 estrogen inhibit treatment-induced increase
4-HT increase
U0126 4-HT no effect upon treatment-induced increase
ICI 182,780 increase
U0126 ICI 182,780 no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.